title: [Change of TK1 Expression Level in NHL Patients before and after Chemotherapy and Its Clinical Significance].
abstract: OBJECTIVE
  To study the change of TK1 expression level in patients with NHL and its clinical significance.
  
  
  METHODS
  A total of 108 NHL patients from July 2013 to January 2016 were chosen, all patients were treated with chemotherapy. The TK1 expression level and TK1 variation rate were compared among CR/PR/PD/DR patients. All patients were followed up, and the relation of TK1 level with OS/PFS was analyzed.
  
  
  RESULTS
  After treatment, the TK1 expression level of CR/PR/SD patients decreased significantly (P<0.05). Before treatment, the TK1 expression level of CR patients was 1.49±0.34,that after treatment was 0.45±0.17,the variation rate was (68.12±5.41)%; those of PR patients were respectively 2.89±0.58, 1.43±0.29 and (50.27±4.82)%; those of PD patients were respectively 3.98±0.78, 3.71±0.85 and (5.04±0.31)%; and those of SD patients were respectively 3.49±0.92, 2.45±0.57 and (28.65±3.97)%, the difference had statistic significance(P<0.05). After treatment, TK1 level related significantly with OS and PFS (P<0.05).
  
  
  CONCLUSIONS
  TK1 expression level has suggested implications for the evaluation of tumor loading, and treatment effect as well as prognosis of patients with NHL.
authors: Department of Laboratorial Examination, The Second Affiliated Hospital of Fujian Medical Universitial, Quanzhou 362000, Fujian Province, China. E-mail: fjwbh258@126.com.
authors: Bao-Hua
authors: BH
authors: Wu
authors: Department of Laboratorial Examination, The Second Affiliated Hospital of Fujian Medical Universitial, Quanzhou 362000, Fujian Province, China.
authors: Shuang-Yin
authors: SY
authors: Liang
authors: Department of Hematology, The Second Affiliated Hospital of Fujian Medical Universitial, Quanzhou 362000, Fujian Province, China.
authors: Xi-Zhe
authors: XZ
authors: Guo
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D006801:Humans; D008228:Lymphoma, Non-Hodgkin; D011379:Prognosis; D016896:Treatment Outcome